Ignite Creation Date:
2025-12-25 @ 4:30 AM
Ignite Modification Date:
2025-12-26 @ 3:33 AM
Study NCT ID:
NCT00855218
Status:
COMPLETED
Last Update Posted:
2017-08-18
First Post:
2009-03-03
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
A Phase II Randomized, Double-blind, Placebo-controlled Study of Sorafenib or Placebo in Combination With Transarterial Chemoembolization (TACE) Performed With DC Bead and Doxorubicin for Intermediate Stage Hepatocellular Carcinoma (HCC).
Sponsor:
Bayer
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2009-03
Start Date Type:
None
Primary Completion Date:
2011-07
Primary Completion Date Type:
ACTUAL
Completion Date:
2013-02
Completion Date Type:
ACTUAL
First Submit Date:
2009-03-03
First Submit QC Date:
None
Study First Post Date:
2009-03-04
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2012-08-23
Results First Submit QC Date:
None
Results First Post Date:
2012-09-24
Results First Post Date Type:
ESTIMATED
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2017-07-18
Last Update Post Date:
2017-08-18
Last Update Post Date Type:
ACTUAL